Increased levels and activation of the IL-17 receptor in microglia contribute to enhanced neuroinflammation in cerebellum of hyperammonemic rats
Por:
Y. ARENAS, A. LÓPEZ-GRAMAJE, C. MONTOLIU, M. LLANSOLA and V. FELIPO
Publicada:
27 abr 2024
Resumen:
Background Patients with liver cirrhosis may show minimal hepatic encephalopathy (MHE) with mild cognitive impairment and motor incoordination. Rats with chronic hyperammonemia reproduce these alterations. Motor incoordination in hyperammonemic rats is due to increased GABAergic neurotransmission in cerebellum, induced by neuroinflammation, which enhances TNF alpha-TNFR1-S1PR2-CCL2-BDNF-TrkB pathway activation. The initial events by which hyperammonemia triggers activation of this pathway remain unclear. MHE in cirrhotic patients is triggered by a shift in inflammation with increased IL-17. The aims of this work were: (1) assess if hyperammonemia increases IL-17 content and membrane expression of its receptor in cerebellum of hyperammonemic rats; (2) identify the cell types in which IL-17 receptor is expressed and IL-17 increases in hyperammonemia; (3) assess if blocking IL-17 signaling with anti-IL-17 ex-vivo reverses activation of glia and of the TNF alpha-TNFR1-S1PR2-CCL2-BDNF-TrkB pathway.Results IL-17 levels and membrane expression of the IL-17 receptor are increased in cerebellum of rats with hyperammonemia and MHE, leading to increased activation of IL-17 receptor in microglia, which triggers activation of STAT3 and NF-kB, increasing IL-17 and TNF alpha levels, respectively. TNF alpha released from microglia activates TNFR1 in Purkinje neurons, leading to activation of NF-kB and increased IL-17 and TNF alpha also in these cells. Enhanced TNFR1 activation also enhances activation of the TNFR1-S1PR2-CCL2-BDNF-TrkB pathway which mediates microglia and astrocytes activation.Conclusions All these steps are triggered by enhanced activation of IL-17 receptor in microglia and are prevented by ex-vivo treatment with anti-IL-17. IL-17 and IL-17 receptor in microglia would be therapeutic targets to treat neurological impairment in patients with MHE.
Filiaciones:
Y. ARENAS:
Ctr Invest Principe Felipe, Lab Neurobiol, Eduardo Primo Yufera 3, Valencia 46012, Spain
Univ Valencia, Fac Med, Dept Patol, Valencia, Spain
INCL Inst Invest Sanitaria, Valencia, Spain
A. LÓPEZ-GRAMAJE:
Univ Valencia, Fac Med, Dept Patol, Valencia, Spain
INCL Inst Invest Sanitaria, Valencia, Spain
C. MONTOLIU:
Univ Valencia, Fac Med, Dept Patol, Valencia, Spain
INCL Inst Invest Sanitaria, Valencia, Spain
M. LLANSOLA:
Ctr Invest Principe Felipe, Lab Neurobiol, Eduardo Primo Yufera 3, Valencia 46012, Spain
:
Ctr Invest Principe Felipe, Lab Neurobiol, Eduardo Primo Yufera 3, Valencia 46012, Spain
gold
|